Charlotte's Web Holdings (CWEB), the Colorado-based hemp and cannabidiol (CBD) wellness company, reported its fourth-quarter and full-year 2025 financial results on March 31, 2026. The company announced a major debt restructuring with British American Tobacco (BAT), the London-headquartered multinational tobacco and nicotine conglomerate. It also confirmed a role in a federally sanctioned Medicare CBD pilot program set to begin April 1, 2026.
The headline transaction converts $55 million in outstanding debentures plus $10 million in accrued interest into equity, effectively eliminating approximately $65 million in debt from the company's balance sheet. Separately, BAT committed an additional $10 million equity investment at a floor price of C$0.94 per share. When the full transaction closes, BAT will own approximately 40% of Charlotte's Web on a non-diluted basis, according to a company press release published via Morningstar.
The structure is a textbook debt-for-equity swap: existing creditors trade their claim on repayment for an ownership stake, reducing immediate cash pressure on the borrower while concentrating control in the hands of the converting party. For Charlotte's Web, a company that has cycled through years of widening losses, removing a $65 million liability is material. For BAT, the transaction quietly positions one of the world's largest tobacco companies as the dominant shareholder of America's best-known CBD brand.
BAT's 40% Stake and What It Means for Charlotte's Web
BAT's deepening involvement in Charlotte's Web is part of the tobacco industry's broader pivot toward alternative nicotine and wellness categories as cigarette volumes decline globally. The company did not issue a detailed strategic statement through the insight packages available, but the mechanics of the deal speak to a long-term positioning play rather than a short-term financial rescue. Charlotte's Web, founded in Colorado and named after a strain of hemp developed to help a child with epilepsy, has built one of the most recognized consumer CBD brands in the United States.
The $10 million fresh equity injection at C$0.94 per share provides working capital while the debt conversion clears the legacy obligation structure. According to Investing.com, the company has made significant strides in cost reduction as it pursues a path to profitability. What the earnings call did not resolve is whether BAT's expanded ownership accelerates that path or introduces its own set of strategic constraints for a brand whose consumer appeal rests partly on natural wellness positioning.
Medicare CBD Pilot Program and the CMS Guidance Shift
The more structurally novel development disclosed during the earnings period is Charlotte's Web's confirmed role as a launch partner in a pilot program administered by the Centers for Medicare and Medicaid Services Innovation Center (CMMI), targeting senior oncology patients. Medicare, the federal health insurance program covering approximately 67 million Americans aged 65 and older or with qualifying disabilities, has not historically covered cannabis-derived or hemp-derived products.
That changed in practical terms when the Centers for Medicare and Medicaid Services (CMS) issued new guidance expanding access to full-spectrum hemp products containing up to 3mg of tetrahydrocannabinol (THC) per serving through what the agency calls the Substance Access Beneficiary Engagement Incentive (BEI) program. Under the BEI program, healthcare organizations can fund up to $500 per Medicare beneficiary annually for eligible CBD wellness products, according to Seeking Alpha. Coverage began April 1, 2026.
The inclusion of full-spectrum products containing trace THC is notable. Federal law caps THC content in hemp-derived products at 0.3% by dry weight, but CMS's 3mg-per-serving threshold introduces a quantity-based standard that could affect how manufacturers formulate products for the Medicare channel. Charlotte's Web's existing full-spectrum product line appears positioned to qualify under this guidance, though the company has not published a product-by-product compliance breakdown in the materials reviewed.
The pilot targets senior oncology patients specifically, a population with documented rates of pain, nausea, and sleep disruption for which CBD products are frequently marketed. Whether CMMI's pilot produces outcomes data sufficient to support a broader Medicare coverage expansion is a multi-year question, and the pilot's scope and duration have not been fully detailed in sources available.
Q4 Loss Widens Even as Full-Year Revenue Turns Positive
The financial results themselves present a split picture. Charlotte's Web posted a Q4 2025 net loss of $11.4 million, or $0.07 per share, a sharp deterioration from the $3.4 million loss recorded in the prior-year quarter, according to TipRanks. The Q3 2025 period showed revenue of US$11.5 million with a basic earnings-per-share loss of $0.04, per Simply Wall St.
Against that backdrop, the full-year 2025 revenue figure delivered what management and observers had not seen in four years: growth. Charlotte's Web posted its first year-over-year sales increase since 2021 in fiscal 2025, according to National Today. The company attributed part of its improving cost profile to operational restructuring, and the earnings call highlighted ongoing efforts to reduce overhead while chasing profitability.
The tension between a widening quarterly loss and a positive annual revenue trend is a familiar feature of cannabis and hemp sector financials, where one-time charges, inventory adjustments, and restructuring costs frequently distort period-level results. The Q4 loss figure has not been reconciled against non-recurring items in the sources reviewed, which limits how cleanly it can be read alongside the full-year revenue improvement.
Tip Ranks noted that its AI Analyst model rates CWEB as "Neutral," citing weak financial performance and balance sheet constraints, though that rating carries a confidence level of 78% in the sourced material and predates the completion of the BAT debt conversion. Once the $65 million liability clears the balance sheet, the constraints underpinning that rating will look materially different on paper.
What Charlotte's Web carries into the second quarter of 2026 is a cleaner balance sheet, a strategically significant corporate partner holding 40% of its equity, a federally enabled distribution channel through Medicare that did not exist a year ago, and a revenue trajectory that, for the first time since 2021, is moving in the right direction. The operational and regulatory execution required to convert those assets into sustained profitability is the work that remains.
Disclaimer: This article was produced with the assistance of artificial intelligence tool but vetted by human editor.
